Gabather: Starting phase II clinical trial - VH Corp

* Approval to initiate the financed TOTEMS study
* Patient enrolment imminent

Gabather has announced the initiation of the TOTEMS study, a phase II clinical trial evaluating the drug candidate GT-002 in patients with schizophrenia spectrum disorders. The study is conducted at the Center for Neuropsychiatric Schizophrenia Research (CNSR) at the Copenhagen University Hospital. Positive preliminary results would be a great boon to the investment case, for now we wait patiently.

Länk till analysen i sin helhet: https://mfn.se/a/vastra-hamnen/gabather-starting-phase-ii-clinical-trial